What it is claimed to help
These are the uses attached to ARA-290 in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Randomised controlled human trials exist. Not necessarily approved, and not necessarily positive.
Genuinely randomised. Phase 2 trials in sarcoidosis-associated small fibre neuropathy and in type 2 diabetes reported improved corneal nerve fibre measures and patient-reported pain. Trials were small and it has not reached approval. Still: more human data than most of the repair peptides sold online.
How it is supposed to work
Selectively activates the innate repair receptor (EPOR/CD131 heteromer) without EPO's erythropoietic effect, so it does not raise haematocrit.
Safety
Well tolerated in trials. Long-term data absent.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- Dahan A et al. ARA-290 in sarcoidosis neuropathy, Mol Med 2013
- Culver DA et al. ARA-290 phase 2
- Brines M et al. Innate repair receptor
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.